BioNTech plans to expand its global footprint to Asia with the establishment of its regional headquarters for Southeast Asia in Singapore. In addition to selecting Singapore as its future regional headquarters, BioNTech plans to establish a fully integrated mRNA manufacturing facility in Singapore with support from the Singapore Economic Development Board.

The new facility will provide regional and global supply capacity of BioNTech’s growing pipeline of mRNA-based product candidates, and is intended to serve as a rapid response production capability for Southeast Asia to address potential pandemic threats.

In line with BioNTech’s mission to develop next-generation immunotherapies to improve the health of individuals worldwide, the new mRNA manufacturing facility will leverage cutting-edge manufacturing and digital infrastructure, according to Ugur Sahin, MD, CEO, and co-founder of BioNTech, adding that it will be equipped to produce a range of novel mRNA vaccines and therapeutics for infectious diseases and cancer.

The envisioned site will bring highly automated and end-to-end mRNA production capabilities across drug substance, drug product, and fill-and-finish, with an estimated annual capacity of several hundred of million doses of mRNA-based vaccines depending on the specific vaccine.

BioNTech plans to open its Singapore office and initiate construction of the manufacturing facility in 2021, subject to planning approval. The company anticipates that the site could be operational as early as 2023 and will create up to 80 jobs in Singapore.

“Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities. With this planned mRNA production facility, we will increase our overall network capacity and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world,” said Sahin.

“Singapore provides an excellent business climate, growing biotechnology industry, and rich talent base. We would like to thank Singapore’s Economic Development Board who has been very supportive throughout our planning process and we look forward to contributing our technology and expertise to the development of the biotechnology industry in Singapore and this region.”

Previous articleDSM Agrees to Evaluate Debut Biotech’s Scalable Cell-Free Manufacturing Platform
Next articleRetroviral Elements Could Be Exploited to Fight Esophageal Cancer